Mr. Rav Mlait reports

CANNABIX TECHNOLOGIES WELCOMES DR. PHILLIP OLLA TO THE BOARD OF DIRECTORS

Dr. Phillip Olla, PhD, has joined the board of directors of Cannabix Technologies Inc. Dr. Olla is an expert in breath technologies, breathomics, health care innovation, and artificial and medical informatics. Dr. Olla has served as the chief executive officer of Audacia Bioscience, a health informatics company who performed substantial work in cannabis breath research and development. Dr. Olla is one of only a handful of scientists globally who has ever conducted delta-9 THC (tetrahydrocannabinol) analysis in blood and breath. Dr. Olla is an associate professor at University of Detroit Mercy in Michigan and is the vice-chair of the MedHealth Consortium.

Dr. Olla has established himself as a sought-after global speaker. He has authored seven books and more than 60 scholarly publications, showcasing his expertise in technology innovation and health care. He worked in the telecom and technology sectors for over a decade, working for British Telecom, O2 and Oracle. His contributions within the digital health arena have been acknowledged internationally, exemplified by his invitation to speak at a United Nations conference and World Health Organization. Notably, his professional journey includes collaborations with companies like IBM, Roche Diagnostics and Morgan Stanley. Dr. Olla holds a PhD in management information systems (MIS) from Brunel University (United Kingdom).

Dr. Olla's contributions to breathomics are particularly noteworthy. His published research in this domain has established him as a leader in understanding the complex interplay of breath components and their potential applications in medical diagnostics.

Rav Mlait, chief executive officer, stated: "Dr. Olla's expertise in multimodal breath analysis will aid in advancing Cannabix's marijuana and alcohol Breathalyzer technologies in the U.S. and Europe. Dr. Olla has amassed a considerable network of industry professionals and experience that will help Cannabix move to commercialization. Dr. Olla will also help explore additional applications and market opportunities for Cannabix's novel breath testing technologies."

Stock options

The company has cancelled 1.5 million stock options as follows: 450,000 options exercisable at 80 cents, 375,000 options exercisable at 50 cents, 500,000 options exercisable at 55 cents and 175,000 options exercisable at 35 cents.

The company is granting a total of 2.7 million incentive stock options to directors and consultants of the company. Of the options, 2,225,000 will be exercisable at 25 cents per share for five years and 475,000 will be exercisable at 25 cents per share for two years, and the options are subject to vesting provisions.

About Cannabix Technologies Inc.

Cannabix Technologies is a developer of marijuana and alcohol Breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is working to develop delta-9 THC and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana that causes impairment. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of contactless breath alcohol detection devices for employers and a host of other settings.

We seek Safe Harbor.